Menu
Search Close

News

SCIB1 Trial Update

17th April 2012

Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer vaccines, is pleased to announce the completion of recruitment to the Phase I clinical trial of SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma. The trial is being conducted in five UK centres in patients with Stage III/IV disease, and it is anticipated that Phase II trials will commence in the next few weeks. 

Scancell has obtained approval from the Cohort Review Committee to commence the Phase II study using the 4mg dose, the highest dose used in the Phase I part of the study. The approval is based upon safety data collected after all patients have been treated for 6 weeks. The Phase I patients will continue to be treated and followed up for a total of 6 months. 

Professor Lindy Durrant, Joint CEO of Scancell Holdings and Professor of Cancer Immunotherapy at Nottingham University, commented: 

“The recruitment of patients to early stage cancer studies can be very challenging and it is a tribute to both the dedicated Scancell team and the efforts of our clinical investigators that we have now completed recruitment for the Phase I part of the study. We expect recruitment for Phase II to be substantially faster than for Phase I and hope to treat the first patient in this part of the study within the next few weeks.” 

For further information contact: 

Enquiries: Scancell Holdings Plc 

Dr Richard Goodfellow / Professor Lindy Durrant 

 

+ 44 (0)20 7653 9850* 

Newgate Threadneedle (Financial PR) 

Guy McDougall/ Heather Armstrong 

 

+ 44 (0)20 7653 9850 

Zeus Capital - Nominated Adviser/Joint Broker 

Ross Andrews/Tom Rowley 

 

+ 44 (0)161 831 1512 

XCAP - Joint Broker 

Jon Belliss/ Adrian Kirk 

 

+44 (0)207 101 7070 

Webcasts, Interviews and Media Coverage

Scancell’s Modi-2 anti-cancer vaccine shows potential in pre-clinical studies

Modi-2 is the second vaccine developed from the Moditope platform after Modi-1, and Scancell thinks each one has the potential to treat different types of cancer

Tue, 30 Oct 2018 14:05:00

Scancell says it is working closely with US regulators ahead of phase II study of cancer immunotherapy

The UK group is planning to use its SCIB1 in harness with Merck’s Keytruda to treat patients with advanced melanoma

Wed, 24 Oct 2018 05:40:00

Scancell Holdings part of the new cancer revolution

The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology

Tue, 25 Sep 2018 06:20:00